Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Odonate Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsOdonate Therapeutics, Inc.

Odonate Therapeutics, Inc.

Also known as:

ODTCD

ODTC

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

15

11 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

12

80.0%

Phase 2

2

13.3%

Phase 3

1

6.7%

Trial Status Distribution

Active, not recruiting

11

73.3%

Terminated

4

26.7%

Clinical Trials

Trials sponsored by this organization (15)

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

Mar 202093 participants

/A

Active, not recruiting

Nov 2019130 participants

/A

Active, not recruiting

Oct 2019130 participants

/A

Active, not recruiting

Oct 2019320 participants

/A

Active, not recruiting

Sep 2019210 participants

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Jul 2019294 participants

/a

Active, not recruiting

Apr 2019125 participants

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Feb 2019152 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials15
Approvals
News

Back to Organizations